Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

In a propensity score-matched analysis including 754 patients ages 50 and up, use of vedolizumab was associated with a 45.4% risk of treatment failure -- defined as a composite risk of IBD-related ...

Use of lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) to predict relapse in patients with diffuse large B-cell lymphoma (DLBCL). Background: Inflammatory bowel disease ...

Vitamin D significantly affects IBD by influencing severity, inflammation, and patient outcomes. Optimizing vitamin D levels ...

Alopecia areata is more prevalent in patients with IBD, especially those on anti-TNF therapy, compared with controls. The study found no significant difference in alopecia improvement between those ...

Patients with rheumatoid arthritis (RA) who used tumor necrosis factor (TNF) inhibitors had significantly higher rates of nonmelanoma skin cancer and non-Hodgkin lymphoma. A new report based on ...

Please provide your email address to receive an email when new articles are posted on . Mirikizumab, a monoclonal antibody poised to become first-in-class treatment for ulcerative colitis, has the ...

Patients with both inflammatory bowel disease (IBD) and obesity starting on new biologic therapies do not face an increased risk for hospitalization, IBD-related surgery, or serious infection, reveals ...

Anti-tumor necrosis factor alpha (TNF-alpha) inhibitors are associated with an increased risk for multiple sclerosis (MS), especially among patients with rheumatic disease (RD), new research shows.

Medically reviewed by Shadi Hamdeh, MDMedically reviewed by Shadi Hamdeh, MD Humira (adalimumab) side effects may include pain, irritation, swelling, or itching at the site of the injection, as well ...